Shares of PharMerica Co. (NYSE:PMC) have been assigned an average recommendation of “Hold” from the seven research firms that are presently covering the company, Marketbeat.com reports. Two analysts have rated the stock with a sell recommendation, three have issued a hold recommendation and two have assigned a buy recommendation to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $29.25.

Several equities analysts recently issued reports on PMC shares. Zacks Investment Research lowered PharMerica from a “buy” rating to a “hold” rating in a research note on Wednesday, October 4th. ValuEngine raised PharMerica from a “hold” rating to a “buy” rating in a research note on Tuesday, October 31st. KeyCorp lowered PharMerica to an “overweight” rating in a research note on Tuesday, August 8th. Finally, Barrington Research lowered PharMerica from an “outperform” rating to an “underperform” rating in a research note on Wednesday, August 9th.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. increased its holdings in PharMerica by 1.9% during the 1st quarter. Vanguard Group Inc. now owns 1,563,866 shares of the company’s stock worth $36,594,000 after purchasing an additional 29,191 shares during the period. Morgan Stanley increased its holdings in PharMerica by 25.2% during the 1st quarter. Morgan Stanley now owns 151,269 shares of the company’s stock worth $3,540,000 after purchasing an additional 30,407 shares during the period. State Street Corp increased its holdings in PharMerica by 5.3% during the 1st quarter. State Street Corp now owns 796,224 shares of the company’s stock worth $18,632,000 after purchasing an additional 40,079 shares during the period. Teachers Retirement System of The State of Kentucky increased its holdings in PharMerica by 15.9% during the 1st quarter. Teachers Retirement System of The State of Kentucky now owns 12,874 shares of the company’s stock worth $301,000 after purchasing an additional 1,770 shares during the period. Finally, State of Alaska Department of Revenue increased its holdings in PharMerica by 79.8% during the 2nd quarter. State of Alaska Department of Revenue now owns 6,112 shares of the company’s stock worth $160,000 after purchasing an additional 2,712 shares during the period. 89.97% of the stock is currently owned by hedge funds and other institutional investors.

PharMerica (NYSE PMC) opened at $29.20 on Wednesday. PharMerica has a 12 month low of $22.00 and a 12 month high of $29.50. The company has a market capitalization of $908.71, a price-to-earnings ratio of 15.15, a PEG ratio of 1.27 and a beta of 0.82. The company has a quick ratio of 1.79, a current ratio of 2.58 and a debt-to-equity ratio of 0.79.

PharMerica (NYSE:PMC) last posted its earnings results on Thursday, November 9th. The company reported $0.46 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.49 by ($0.03). PharMerica had a return on equity of 10.94% and a net margin of 0.83%. The firm had revenue of $595.10 million for the quarter, compared to analyst estimates of $596.80 million. sell-side analysts expect that PharMerica will post 1.92 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “PharMerica Co. (PMC) Given Consensus Rating of “Hold” by Brokerages” was published by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The legal version of this report can be accessed at https://www.americanbankingnews.com/2017/12/06/pharmerica-co-pmc-given-consensus-rating-of-hold-by-brokerages.html.

About PharMerica

Receive News & Ratings for PharMerica Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PharMerica Co. and related companies with MarketBeat.com's FREE daily email newsletter.